AI & Multi-omics for Translational Research

The future of translational research and the most exciting advances are happening at the intersection of AI, multi-omics, biomarker development, and biospecimen strategy, each essential for capturing the biological variability that shapes precision medicine. This panel brings together scientists, technologists, and strategists driving the next generation of biomarker & diagnostic discovery and validation. 

You’ll hear from leaders at Precision for Medicine, SOPHiA GENETICS, and Olink, part of Thermo Fisher Scientific; partners at the forefront of multi-omics integration, AI-powered analytics, genomics and high-plex proteomics as they discuss leading-edge practices and where the field is headed in 2026. 

Key takeaways from the session:

Perspectives from Industry Leaders: Hear from the teams behind the most innovative AI, genomic and proteomic technologies used by top biopharma companies. 

Strategic Integration Discussion: Explore how aligning biospecimen planning, assay development, and data analytics, powered by multi-omics, can enable more predictive biomarkers for clinical decision-making. 

Implementation Framework: Gain a practical roadmap for connecting AI to multi-omic assay workflows, how to implement a successful biospecimen strategy, and how to build a successful multi-omic strategy